title: Current issues regarding the use of drotrecogin alfa (activated).
abstract: The key issues clinicians are facing regarding drotrecogin alfa (activated) include questions concerning the pathophysiology and appropriate patient selection for administration of this drug. In the Recombinant Human Activated Protein C Worldwide Evaluation in Severe Sepsis (PROWESS) trial, the efficacy of drotrecogin alfa (activated) was demonstrated in patients with severe sepsis. Because of this trial's strict inclusion and exclusion criteria, however, the applicability of the study criteria to different types of patients raises important issues. Coupling the data from the PROWESS trial with additional information being gained from expanding clinical experience, as well as additional studies, clinicians will be able to better understand and refine the use of activated protein C within their respective practices.
authors.affiliation: Pharmacotherapy Services, VISICU, Baltimore, Maryland 21224, USA. ehassan@visicu.com
authors.forename: Erkan
authors.initials: E
authors.lastname: Hassan
authors.forename: Henry J
authors.initials: HJ
authors.lastname: Mann
mesh_terms: D000890:Anti-Infective Agents / Q000008:administration & dosage*; D004334:Drug Administration Schedule; D006801:Humans; D018579:Patient Selection; D011486:Protein C / Q000008:administration & dosage*; D016032:Randomized Controlled Trials as Topic; D011994:Recombinant Proteins / Q000008:administration & dosage*; D018805:Sepsis / Q000188:drug therapy* / Q000473:pathology; D012720:Severity of Illness Index
chemical_list: D000890:Anti-Infective Agents; D011486:Protein C; D011994:Recombinant Proteins; C421124:drotrecogin alfa activated